Wells Fargo & Company upgraded shares of Zimmer Biomet (NYSE:ZBH – Free Report) from an equal weight rating to an overweight rating in a research report released on Tuesday morning, Marketbeat Ratings reports. The firm currently has $123.00 target price on the medical equipment provider’s stock, up from their prior target price of $113.00.
Other research analysts also recently issued research reports about the company. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, November 14th. BMO Capital Markets decreased their target price on shares of Zimmer Biomet from $102.00 to $101.00 and set a “market perform” rating on the stock in a research note on Monday. Jefferies Financial Group reiterated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a report on Wednesday, November 4th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Truist Financial set a $114.00 price target on shares of Zimmer Biomet in a report on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $114.32.
View Our Latest Report on Zimmer Biomet
Zimmer Biomet Stock Performance
NYSE:ZBH opened at $101.30 on Tuesday. The company has a market capitalization of $19.17 billion, a price-to-earnings ratio of 12.18, a PEG ratio of 2.42 and a beta of 0.50. The business has a 50 day moving average of $96.35 and a 200 day moving average of $92.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.79. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $112.54.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the firm posted $1.90 earnings per share. On average, sell-side analysts predict that Zimmer Biomet will post 8.56 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.30%.
Insider Activity at Zimmer Biomet
In related news, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Zimmer Biomet
Institutional investors and hedge funds have recently modified their holdings of the stock. Cim Investment Management Inc. purchased a new stake in shares of Zimmer Biomet in the third quarter worth $331,000. Innovator Capital Management LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at $941,000. Liontrust Investment Partners LLP purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth about $839,000. Allworth Financial LP raised its position in shares of Zimmer Biomet by 37.2% in the 3rd quarter. Allworth Financial LP now owns 3,030 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 821 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Zimmer Biomet by 5.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,021,307 shares of the medical equipment provider’s stock worth $90,723,000 after purchasing an additional 52,679 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
Further Reading
- Five stocks we like better than Zimmer Biomet
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
